IDEXX Laboratories, Inc. (NASDAQ:IDXX) Director Sells $1,397,820.00 in Stock

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the sale, the director now directly owns 3,061 shares in the company, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

IDEXX Laboratories Price Performance

Shares of NASDAQ:IDXX opened at $457.35 on Thursday. IDEXX Laboratories, Inc. has a 12 month low of $398.50 and a 12 month high of $583.39. The company has a current ratio of 1.31, a quick ratio of 1.03 and a debt-to-equity ratio of 0.28. The stock has a market cap of $37.45 billion, a P/E ratio of 42.86, a P/E/G ratio of 3.47 and a beta of 1.37. The company has a 50 day moving average of $429.67 and a 200 day moving average of $453.23.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, February 5th. Bank of America boosted their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research note on Tuesday, February 4th. Leerink Partnrs upgraded shares of IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Morgan Stanley lowered their price target on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 29th. Finally, Piper Sandler raised their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a report on Monday. Four investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, IDEXX Laboratories presently has an average rating of “Moderate Buy” and an average price target of $533.75.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. FSA Wealth Management LLC bought a new stake in IDEXX Laboratories during the third quarter valued at $25,000. E Fund Management Hong Kong Co. Ltd. raised its holdings in shares of IDEXX Laboratories by 5,700.0% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock valued at $29,000 after acquiring an additional 57 shares in the last quarter. Rialto Wealth Management LLC bought a new stake in shares of IDEXX Laboratories during the 4th quarter valued at about $30,000. Retirement Wealth Solutions LLC purchased a new position in shares of IDEXX Laboratories during the fourth quarter worth about $31,000. Finally, Mowery & Schoenfeld Wealth Management LLC increased its position in shares of IDEXX Laboratories by 750.0% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock worth $34,000 after purchasing an additional 60 shares during the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.